Drug Trial Radar · NCT04851964
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Apr 22, 2021
Primary completion
Sep 23, 2024
Study completion Dec 11, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Apr 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: TezepelumabBiological
Tezepelumab subcutaneous injection
PlaceboOther
Placebo subcutaneous injection
Mometasone furoate or equivalent intranasal corticosteroidDrug
Background MFNS or equivalent INCS at stable dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Nasal Polyp Score at Week 52Time frame: Baseline to Week 52
- Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52Time frame: Baseline to Week 52
Locations
112 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Bakersfield, California
Research Site
Newport Beach, California
Research Site
Roseville, California
Research Site
Walnut Creek, California
Research Site
Colorado Springs, Colorado
Research Site
Denver, Colorado
Research Site
Boca Raton, Florida
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
White Marsh, Maryland
Research Site
Boston, Massachusetts
Research Site
Columbia, Missouri
Research Site
New York, New York
Research Site
Winston-Salem, North Carolina
Research Site
Oklahoma City, Oklahoma
Research Site
North Charleston, South Carolina
Research Site
Dallas, Texas
Research Site
Norfolk, Virginia
Research Site
Spokane, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Vancouver, British Columbia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Bengbu, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hengyang, China
Research Site
Lanzhou, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.